Gas tamponade linked to better vision outcomes than silicon oil

gas-tamponade-linked-to-better-vision-outcomes-than-silicon-oil.jpg

MAR 20, 2018

Retina/Vitreous


The authors investigated the effect of 2 tamponading agents on retinal thickness in eyes that underwent surgery for macula-on retinal detachment (RD).

Study design

The retrospective analysis included 33 eyes that received silicone oil tamponade and 31 eyes that received gas tamponade for the treatment of rhegmatogenous RD. The primary outcome measure was the change in thickness of each retinal layer in the central 1 mm zone, as determined by spectral domain OCT.

Outcomes

At 6 months postop, eyes in the silicone oil group had a statistically significant decrease in total retinal thickness. All retinal layers, with the exception of the photoreceptor layer, were significantly thinner (P<0.001). In contrast, eyes in the gas group did not experience any significant changes in total retinal thickness or in the measurements of any individual retinal layer.

Postoperative BCVA in the silicone oil group was significantly worse than the gas group at 6 and 9 months (P=0.003 and P=0.004, respectively).

Postoperative decreases in the ganglion cell layer, outer plexiform layer and outer nuclear layer thicknesses significantly correlated with worse BCVA in the silicone oil group (all P<0.05).

Limitations

The study is retrospective and patients were not randomized. The choice of agent was based on surgeon preference.

Clinical significance

Although the pathogenic mechanism of silicone oil toxicity remains unclear, the findings here suggest that silicone oil tamponade leads to poorer vision outcome than gas agents. OCT segmentation analysis could prove useful for detecting early retinal thinning in patients treated with silicone oil tamponade.

View Abstract Retina, February 2018

https://www.aao.org/editors-choice/gas-tamponade-linked-to-better-vision-outcomes-tha

Comments

Post a Comment

Popular posts from this blog

Week in review: Pay raise, Von’s Vision, gonio-<em>what?</em>

Image
APR 13, 2018 By Anni Griswold Comprehensive Ophthalmology, Cornea/External Disease, Glaucoma, Pediatric Ophth/Strabismus Above: The GonioPEN (Credit: Nanyang Technological University) A weekly roundup of ophthalmic news from around the web. Ophthalmologists earn more than the average physician , and their salaries are on the rise (+3% over the last year, to be precise). Eye docs will earn a mean $375,000 this year—more than the physician average of $299,000, but well below a typical plastic surgeon’s paycheck. See for yourself in Medscape’s 2018 Physician Compensation Report . Medscape A special supplement to USA Today will highlight the work of Von Miller , a 28-year-old linebacker for the Denver Broncos and former Super Bowl MVP. Through his foundation, Von’s Vision, Miller connects thousands of underprivileged children in Denver with affordable, high-quality eye care. His interview will appear in the “Vision Health” campaign during World Glaucoma Week, available in pr...
Read more

Patch with Microneedles Could Replace Eye Injections

Image
Instead of getting eye injections, patients with serious eye diseases may be eligible for a contact lens-type patch. 1 Injections are often recommended for eye diseases such as Wet (advanced) Age-Related Macular Degeneration, macular edema, and glaucoma. The new patch is inserted painlessly like a contact lens. It delivers tiny microneedles containing medication. The microneedles are made from natural materials and dissolve over time, gradually releasing medicine. Patients would be more likely to stick with a regimen that does not involve eye injections. Eye Injections: Stick a Needle in My Eye Patients generally dread eye injections. Injections must be performed in a doctor’s office. Eye injections can be painful, and they are inconvenient. They can introduce infection. And they can damage the eye. Avastin, Eylea, and Lucentis are injectable medications that discourage new blood vessel growth. These anti-VEGF medicines are useful for advanced Macular Degeneration , Diabetic Retino...
Read more

Incidence of eyelid SCC appears to be rising

FEB 12, 2018 Oculoplastics/Orbit This retrospective study examined demographic risk factors for developing eyelid squamous cell carcinoma (SCC). Study design Using data from the National Cancer Registration and Analysis Service, investigators identified all cases of eyelid SCC in England between 2000 and 2014. Outcomes Over the 15-year study period, there were 4,022 patients with newly diagnosed SCC affecting the eyelid. The age-standardized number of reported cases of eyelid SCC rose approximately 2% per year over the study period. The risk for developing an eyelid SCC approximately doubled each decade after age 60. Men were at 1.9-times greater relative risk compared with women. The authors did not find any association between income quintile and risk of SCC. Limitations The cause for the increasing incidence of eyelid SCC was not studied. While age may represent one factor, others such as an increasing rate of patients receiving immunosuppression therapies may als...
Read more